

Biocon Biologics' Insugen bags three-year contract from Ministry of Health, Malaysia

26 April 2022 | News

Biocon Biologics' Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics

Indian firm Biocon Biologics' subsidiary Biocon in Malaysia has been awarded a three-year contract, valued at \$90 million (MYR 375 million), for its recombinant human insulin brand Insugen, by the Ministry of Health (MoH), Malaysia.

Biocon, a subsidiary of Biocon Biologics in Malaysia, will manufacture and supply its range of insulins to its partner Duopharma Marketing (DMktg), a subsidiary of Duopharma Biotech, a leading pharmaceutical and biotech company in Malaysia.

Biocon Biologics' Insugen formulations will be available to patients at all Ministry of Health hospitals, district health offices and health clinics.

The rh-Insulin formulations, Insugen-R, Insugen-N and Insugen-30/70, are manufactured at Biocon's Johor facility and have been approved by the National Pharmaceutical Regulatory Authority (NPRA), Malaysia.

Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins. The state-of-the-art insulins facility in Johor, is the first and only biopharmaceutical sterile injectables facility in Malaysia to receive US FDA and EMA approval. More recently, Biocon's biosimilar insulin Glargine made in Malaysia has received a historic US FDA approval as the 'first interchangeable biosimilar'.